

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 54377

Title: Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report

Reviewer's code: 02994003

Position: Editorial Board

Academic degree: PhD

Professional title: Professor, Research Scientist

Reviewer's Country/Territory: Egypt

Author's Country/Territory: China

Manuscript submission date: 2020-01-26

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-01-26 14:27

Reviewer performed review: 2020-02-04 11:30

Review time: 8 Days and 21 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Manuscript ID: 54377 Manuscript Title: Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report All Author List: Ping Chen, Min Yu, Jiliang Zhang, Weiyong Chen, Li Zhu, Yue Song, Chengyi Jiang and Shuang Zhang Manuscript Type: Case Report 1-Title reflected the main subject/hypothesis of the manuscript. 2-The abstract summarized and reflect the work described in the manuscript? 3- key words reflected the focus of the manuscript 4 -The manuscript adequately described the background, presented status and significance of the study 5-The manuscript described methods (e.g., experiments, data analysis, surveys, and clinical trials, etc.) in adequate detail 6 -The research objectives are achieved by the experiments used in this study. Authors suggested that the combination of radiotherapy and immunotherapy based on human monoclonal antibodies (pembrolizumab), may elevate treatment efficacy 7- The manuscript interpreted the findings adequately and appropriately, highlighting the key points concisely, clearly and logically 8-Manuscript included sufficient, good quality figures 9-Manuscript type is case report 10 -The manuscript meet the requirements of use of SI units 11-The manuscript cited appropriately the latest, important and authoritative references in the introduction and discussion sections. The author self-cited 12-The manuscript is well, concisely and coherently organized and presented and the style, language and grammar are accurate and appropriated 13 Authors have prepared their manuscripts according to manuscript type and the appropriate categories, except legend of figure. Author wrote legends above figures -Authors findings highlighted and offer direct evidence of the efficacy of pembrolizumab in PD-L1-overexpression PSCs. Combined radiotherapy and immunotherapy may elevate the treatment efficacy. -The limitations of the study is use only one dose of human monoclonal antibodies



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

(pembrolizumab) and then they stop due to fever and infection. So are sure the finding and clearance of the tumor is due to radiotherapy only or due to continue with one dose of immunotherapy

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 54377

Title: Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report

Reviewer's code: 00188507

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Doctor, Lecturer

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2020-01-26

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-02-05 03:27

Reviewer performed review: 2020-02-05 03:35

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The author reported the case of PSC expressing PD-L1 and reflected to the pembrolizumab. The diagnosis and clinical courses are reasonably demonstrated and the conclusions showing the importance of combination therapy with radiotherapy, surgical removal is reasonable. Therefore, this report can be considered for the publication in this journal.